Skip to Content
Morningstar

Curaleaf Holdings Inc CURA

Morningstar Rating
Unlock
Stock XTSE Rating as of
CAD 6.28 −0.08 (1.26%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Curaleaf Earnings: Few Surprises but Still Well-Positioned for Many Tailwinds; Shares Undervalued

Kristoffer Inton

No-moat Curaleaf reported steady first-quarter results that were within our expectations. Sequentially, net revenue shrank 2%, reflecting the seasonality in the business. Moreover, Curaleaf’s adjusted EBITDA margin of 23% remained within range of recent quarters. Management maintained full-year guidance for mid-single-digit revenue growth and adjusted EBITDA margin in the mid-20% range. This compares with our preresults forecasts of 6% and 25%, respectively. As such, we expect minimal changes to our USD 13/CAD 17.50 fair value estimates. We continue to see Curaleaf as one of the most attractively priced cannabis stocks.

Read Full Report

Price vs Fair Value

View History
CURA is trading within a range we consider fairly valued.
Price
CAD 6.28
Fair Value
CAD 88.20
Uncertainty
Very High
1-Star Price
CAD 65.89
5-Star Price
CAD 3.73
Economic Moat
Tswy
Capital Allocation
Jsmlvdzf

Bulls Say, Bears Say

Bulls

Unique among US multistate operators, Curaleaf's acquisitions into Europe and Canada allow it to serve the growing European market as legalization expands.

Bears

Sales growth for legal sellers like Curaleaf are challenged by the lack of taxes in the illicit market.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CURA is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
CAD 6.36
Day Range
CAD 6.14–6.31
52-Week Range
CAD 4.58–8.73
Bid/Ask
CAD 6.18 / CAD 6.18
Market Cap
CAD 4.66 Bil
Volume/Avg
185,769 / 498,031

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
2.50
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
5,650
Website
https://www.curaleaf.com

Competitors

Valuation

View More
Metric
CURA
TLRY
GTII
Price/Earnings (Normalized)
 ——35.41
Price/Book Value
 3.370.431.53
Price/Sales
 2.501.782.50
Price/Cash Flow
 52.14—9.95
Price/Earnings
CURA
TLRY
GTII

Financial Strength

Metric
CURA
TLRY
GTII
Quick Ratio
 0.290.961.58
Current Ratio
 0.721.922.40
Interest Coverage
 −0.31−4.398.44
Quick Ratio
CURA
TLRY
GTII

Profitability

Metric
CURA
TLRY
GTII
Return on Assets (Normalized)
 −3.72%−1.42%3.06%
Return on Equity (Normalized)
 −10.45%−1.82%4.55%
Return on Invested Capital (Normalized)
 −2.20%−0.92%3.80%
Return on Assets
CURA
TLRY
GTII
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
MKKGY
Merck KGaA ADRHdcfdknwwxYgxsrs$78.9 Bil
ZTS
Zoetis Inc Class ALrkxkbxxclXgl$77.6 Bil
HLN
Haleon PLC ADRDdcbcmsTjyd$37.6 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRNyrstlxpzVwyr$18.8 Bil
VTRS
Viatris IncKpwxrmxmTjtv$12.4 Bil
RDY
Dr Reddy's Laboratories Ltd ADRMybdbrrGvcg$11.8 Bil
CTLT
Catalent IncHfmcmcjXxxxg$9.9 Bil
PRGO
Perrigo Co PLCDxkdkwrMzhg$3.8 Bil
CURLF
Curaleaf Holdings IncCjdfmzccHxs$3.4 Bil
PBH
Prestige Consumer Healthcare IncBfftzgtqbKqlbkff$3.2 Bil

Sponsor Center